Pharming Group N.V. financials
Also U.S.-listed. Pharming Group N.V. is also a foreign private issuer filing with the U.S. SEC. View its EDGAR financials: PHAR — Pharming Group N.V.
Pharming Group N.V.
Country: NL Reporting currency: USD Latest annual report: 2025-12-31
LEI:
724500DCJ9MPG74JEH91 Financial statements
(USD, as reported — unscaled; 104 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | $376.1M | $297.2M |
| Cost of sales | $45.5M | $35.4M |
| Gross profit | $330.6M | $261.8M |
| Other income | $6.5M | $2.2M |
| Administrative expenses | $80.0M | $70.7M |
| Operating expenses | $311.3M | $272.6M |
| Operating profit (EBIT) | $25.8M | -$8.6M |
| Net finance income / (cost) | -$13.6M | $1.9M |
| Finance costs | $18.1M | $9.9M |
| Profit before tax | $12.8M | -$8.5M |
| Income tax expense | $10.3M | $3.3M |
| Profit for the year | $2.5M | -$11.8M |
| — attributable to owners | $2.9M | -$11.8M |
| — attributable to NCI | -$313.0K | $0 |
| Total comprehensive income | $31.6M | -$23.7M |
| Per share | ||
| Basic EPS | $0.00 | $-0.02 |
| Diluted EPS | $0.00 | $-0.02 |
| Free cash flow / share | $0.09 | $-0.00 |
| Cash flow statement | ||
| Net cash from operating activities | $54.7M | -$1.8M |
| Net cash from investing activities | $26.3M | $31.6M |
| Purchase of PP&E (capex) | $749.0K | $790.0K |
| Purchase of intangibles | $6.0K | $6.0K |
| Net cash from financing activities | $1.5M | -$34.4M |
| Lease liability payments | $4.2M | $4.0M |
| Net change in cash | $82.5M | -$4.6M |
| Balance sheet | ||
| Total assets | $500.0M | $400.0M |
| Non-current assets | $200.5M | $121.5M |
| Property, plant & equipment | $7.2M | $7.8M |
| Right-of-use assets | $16.7M | $16.4M |
| Current assets | $299.5M | $278.4M |
| Inventories | $64.9M | $55.7M |
| Trade & other receivables | $54.7M | $54.8M |
| Cash & equivalents | $145.3M | $54.9M |
| Total equity | $277.1M | $221.1M |
| Non-current liabilities | $107.1M | $105.1M |
| Lease liabilities (non-current) | $14.4M | $27.0M |
| Current liabilities | $115.8M | $73.8M |
| Lease liabilities (current) | $3.4M | $2.9M |
| Trade & other payables | $105.9M | $66.6M |
| Derived metrics | ||
| Free cash flow | $54.0M | -$2.6M |
| Operating margin | 6.9% | -2.9% |
| Net margin | 0.7% | -4.0% |
| Return on equity | 0.9% | -5.4% |
| Cash conversion ratio | 21.56× | 0.15× |
| Capex coverage | 73.04× | -2.27× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -$1.3M | -$503.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | -$3.4M | -$6.8M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | $11.2M | $16.1M |
| Adjustments For Fair Value Gains Losses | -$2.3M | -$5.0M |
| Adjustments For Finance Costs | $17.9M | $9.9M |
| Adjustments For Finance Income | $2.2M | $6.8M |
| Adjustments For Increase Decrease In Trade and Other Payables | $14.1M | -$2.8M |
| Adjustments For Provisions | $1.2M | $0 |
| Adjustments For Sharebased Payments | $13.8M | $11.2M |
| Adjustments For Undistributed Profits of Associates | $623.0K | -$1.8M |
| Cash Flows From Used In Decrease Increase In Restricted Cash and Cash Equivalents | -$285.0K | -$17.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | $46.9M | $18.7M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | $57.5M | — |
| Comprehensive Income Attributable To Noncontrolling Interests | -$230.0K | $0 |
| Comprehensive Income Attributable To Owners of Parent | $31.8M | -$23.7M |
| Current Bonds Issued and Current Portion of Noncurrent Bonds Issued | $5.3M | $4.2M |
| Current Provisions | $1.2M | $0 |
| Current Restricted Cash and Cash Equivalents | $761.0K | $0 |
| Decrease Increase Through Tax On Sharebased Payment Transactions | -$1.3M | $66.0K |
| Deferred Tax Assets | $31.0M | $30.5M |
| Dividends Recognised As Distributions To Noncontrolling Interests | $0 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | $7.9M | -$2.2M |
| Equity and Liabilities | $500.0M | $400.0M |
| Finance Income | $2.2M | $6.8M |
| Gains Losses On Financial Assets At Fair Value Through Profit Or Loss | $2.3M | $5.0M |
| Income Taxes Paid Refund Classified As Operating Activities | $4.6M | $15.6M |
| Increase Decrease In Working Capital | -$10.4M | $10.1M |
| Increase Decrease Through Acquisition of Subsidiary | $7.3M | — |
| Increase Decrease Through Conversion of Convertible Instruments | — | $12.2M |
| Increase Decrease Through Other Distributions To Owners | $7.9M | — |
| Increase Decrease Through Sharebased Payment Transactions | $13.8M | $11.2M |
| Increase Decrease Through Transfer To Statutory Reserve | $0 | $0 |
| Intangible Assets Other Than Goodwill | $135.5M | $61.0M |
| Interest Received Classified As Operating Activities | $2.1M | $5.2M |
| Investment Accounted For Using Equity Method | $1.9M | $466.0K |
| Issued Capital | $8.0M | $7.8M |
| Noncurrent Financial Assets At Fair Value Through Profit Or Loss | $6.7M | $3.8M |
| Noncurrent Portion of Noncurrent Bonds Issued | $92.7M | $78.2M |
| Noncurrent Prepayments | $94.0K | $90.0K |
| Noncurrent Restricted Cash and Cash Equivalents | $1.2M | $1.5M |
| Other Comprehensive Income | $29.1M | -$11.9M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | $29.1M | -$12.0M |
| Other Comprehensive Income Net of Tax Gains Losses From Investments In Equity Instruments | $0 | $79.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | $29.1M | -$12.0M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | $0 | $79.0K |
| Other Reserves | $28.8M | -$209.0K |
| Payments From Changes In Ownership Interests In Subsidiaries | $7.9M | $0 |
| Proceeds From Issue of Bonds Notes and Debentures | $0 | $104.5M |
| Proceeds From Issuing Other Equity Instruments | $19.8M | $5.6M |
| Proceeds From Other Longterm Assets Classified As Investing Activities | $224.0K | $2.1M |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | $85.0M | $314.6M |
| Purchase of Financial Instruments Classified As Investing Activities | $2.0K | $284.3M |
| Purchase of Interests In Investments Accounted For Using Equity Method | $739.0K | $0 |
| Repayments of Bonds Notes and Debentures | $0 | $134.9M |
| Research and Development Expense | $100.4M | $83.1M |
| Retained Earnings | -$273.0M | -$275.5M |
| Sales and Marketing Expense | $131.0M | $118.8M |
| Share of Profit Loss of Associates Accounted For Using Equity Method | $623.0K | -$1.8M |
| Share Premium | $513.3M | $489.0M |
Methodology
Every line item above is a fact tagged in Pharming Group N.V.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.